We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+10.75%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3B
AUM Growth
-$85.7M
Cap. Flow
-$518M
Cap. Flow %
-17.24%
Top 10 Hldgs %
35.54%
Holding
152
New
30
Increased
26
Reduced
33
Closed
32

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$60.8M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$55.6M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$40.9M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$39.9M
5
DYAX
DYAX CORPORATION
DYAX
+$35.8M

Top Sells

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$446M
2
ABBV icon
AbbVie
ABBV
+$89.8M
3
ADVM
Adverum Biotechnologies
ADVM
+$85.8M
4
BLUE
bluebird bio
BLUE
+$47.9M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$27.7M

Sector Composition

Rank Sector Weight
1 Healthcare 70.77%
2 Financials 3.42%
3 Technology 0.52%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHDX
26
DELISTED
Genomic Health, Inc.
GHDX
$32.9M 1.1%
+1,183,000
New +$33.4M
ARNA
27
DELISTED
Arena Pharmaceuticals Inc
ARNA
$32.4M 1.08%
698,371
-224,567
-24% -$9.74M
XNCR icon
28
Xencor
XNCR
$1.45B
$31M 1.03%
1,411,000
-484,535
-26% -$8.26M
MCK icon
29
McKesson
MCK
$97.5B
$30.6M 1.02%
136,000
+44,000
+48% +$10.2M
EW icon
30
Edwards Lifesciences
EW
$49.3B
$30.2M 1.01%
+1,271,100
New +$28.7M
ZLTQ
31
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$30M 1%
+1,016,453
New +$30.7M
TVTY
32
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$29.5M 0.98%
+2,465,042
New +$40.9M
GI
33
DELISTED
EndoChoice Holdings, Inc.
GI
$29.4M 0.98%
+1,797,709
New +$29.9M
INFI
34
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$27M 0.9%
2,465,129
-1,503,026
-38% -$19.3M
INGN icon
35
Inogen
INGN
$171M
$26.8M 0.89%
601,772
– –
LOXO
36
DELISTED
Loxo Oncology, Inc
LOXO
$26.1M 0.87%
1,450,151
-141,395
-9% -$1.93M
BSX icon
37
Boston Scientific
BSX
$65.6B
$24.9M 0.83%
+1,405,348
New +$25.1M
ELV icon
38
Elevance Health
ELV
$83.1B
$23.1M 0.77%
140,806
+41,064
+41% +$6.56M
TARA icon
39
Protara Therapeutics
TARA
$230M
$22.6M 0.75%
31,634
– –
SAGE
40
DELISTED
Sage Therapeutics
SAGE
$22.3M 0.74%
305,000
-290,443
-49% -$18.7M
INSM icon
41
Insmed
INSM
$23.5B
$21.8M 0.73%
891,546
-736,985
-45% -$16.7M
NUVA
42
DELISTED
NuVasive, Inc.
NUVA
$21.3M 0.71%
450,272
+112,078
+33% +$5.24M
ELOS
43
DELISTED
Syneron Medical Ltd
ELOS
$21M 0.7%
1,973,945
+1,348,352
+216% +$15.8M
ALIM
44
DELISTED
Alimera Sciences
ALIM
$20.4M 0.68%
294,705
– –
ZVRA icon
45
Zevra Therapeutics
ZVRA
$734M
$19.9M 0.66%
+67,778
New +$14.8M
NSTG
46
DELISTED
NanoString Technologies, Inc.
NSTG
$19M 0.63%
1,232,696
-227,956
-16% -$3.05M
RAD
47
DELISTED
Rite Aid Corporation
RAD
$15.8M 0.53%
94,500
+91,862
+3,482% +$15.4M
IMPR
48
DELISTED
IMPRIVATA, INC COM
IMPR
$15.7M 0.52%
958,152
-67,500
-7% -$1.01M
OFIX icon
49
Orthofix Medical
OFIX
$468M
$15.2M 0.51%
457,699
-172,523
-27% -$5.93M
AKRX
50
DELISTED
Akorn Inc
AKRX
$15M 0.5%
+344,667
New +$15.9M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2015 Portfolio in Review

As of Q2 2015, Deerfield Management held 152 positions worth $3B, down 2.8% from $3.09B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Deerfield Management withdrew a net $518M in Q2 2015, closing 32 positions and reducing 33 holdings. Its most notable exit was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $446M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 60% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Alpine Immune Sciences Inc worth $56.5M.

  • Deerfield Management's largest Q2 2015 buy was Alpine Immune Sciences Inc: 933,103 shares worth $56.5M.
  • Deerfield Management added most to Viatris in Q2 2015, an estimated $60.8M increase.
  • Deerfield Management's biggest Q2 2015 reduction was bluebird bio, cutting an estimated $47.9M.
  • Deerfield Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $446M.
  • Deerfield Management's ten largest holdings make up 36% of its $3B portfolio in Q2 2015.
  • Deerfield Management opened 30 new positions and closed 32 in Q2 2015.
  • Deerfield Management's portfolio value fell 2.8% quarter-over-quarter to $3B.

Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.